Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in leukemia and lymphoma.
Clinical Insights on TLS Prophylaxis With Venetoclax in CLL
Mark Geyer, MD, and Yannis K. Valtis, MD, discussed real-world findings on the incidence, prevention, and management of tumor lysis syndrome in patients with CLL treated with venetoclax.
Read More
Understanding the Role of Zanubrutinib for the Treatment of CLL
Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.
Listen
Englumafusp Alfa/Glofitamab Combo Delivers Early Responses in Patients with NHL
The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.
Exciting Activity in Chronic Lymphocytic Leukemia
In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.
Second-Gen BTKi Drugs Outperform Ibrutinib in CLL/SLL: Real-World Study Shows Promise for Acalabrutinib and Zanubrutinib
Acalabrutinib and zanubrutinib showed longer median TTD and TTNT compared to ibrutinib in CLL/SLL patients. Cardiovascular adverse effects were less frequent with acalabrutinib and zanubrutinib than with ibrutinib.
Rhodes Evaluates Toxicity Concerns With ABVD and Brentuximab Vedotin in cHL
During a Case-Based Roundtable® event, Joanna M. Rhodes, MD, MSCE, discussed issues related to toxicity and dose modification in treating patients with Hodgkin lymphoma.